Durvalumab in Pediatric and Adolescent Patients
NCT02793466
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumor
Lymphoma
Central Nervous System Tumors
Interventions
DRUG:
Durvalumab; MEDI4736
Sponsor
Leo Mascarenhas